JP2013501791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501791A5 JP2013501791A5 JP2012524769A JP2012524769A JP2013501791A5 JP 2013501791 A5 JP2013501791 A5 JP 2013501791A5 JP 2012524769 A JP2012524769 A JP 2012524769A JP 2012524769 A JP2012524769 A JP 2012524769A JP 2013501791 A5 JP2013501791 A5 JP 2013501791A5
- Authority
- JP
- Japan
- Prior art keywords
- temozolomide
- paclitaxel
- brain metastasis
- combination
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004556 brain Anatomy 0.000 claims 9
- 206010027476 Metastases Diseases 0.000 claims 8
- 229930012538 Paclitaxel Natural products 0.000 claims 8
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 8
- 230000009401 metastasis Effects 0.000 claims 8
- 229960001592 paclitaxel Drugs 0.000 claims 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 8
- 229960004964 temozolomide Drugs 0.000 claims 8
- 238000001959 radiotherapy Methods 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 claims 3
- 229960001039 macitentan Drugs 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000002719 stereotactic radiosurgery Methods 0.000 claims 1
Claims (6)
- マシテンタンと、パクリタキセル、テモゾロミドならびにパクリタキセルおよびテモゾロミドの混合物からなるグループから選択される細胞毒性化学療法剤との併用、放射線療法との併用、または放射線療法およびパクリタキセル、テモゾロミドならびにパクリタキセルおよびテモゾロミドの混合物からなるグループから選択される細胞毒性化学療法剤との併用を特徴とする、脳転移の予防または治療剤。
- マシテンタンと、パクリタキセル、テモゾロミドならびにパクリタキセルおよびテモゾロミドの混合物からなるグループから選択される細胞毒性化学療法剤との併用である、請求項１記載の脳転移の予防または治療剤。
- マシテンタンと放射線療法との併用である、請求項１記載の脳転移の予防または治療剤。
- 放射線療法が全脳放射線療法または定位放射線手術である、請求項３記載の脳転移の予防または治療剤。
- マシテンタンと、放射線療法およびパクリタキセル、テモゾロミドならびにパクリタキセルおよびテモゾロミドの混合物からなるグループから選択される細胞毒性化学療法剤との併用である、請求項１記載の脳転移の予防または治療剤。
- 脳転移の危険性の低減および／または脳転移の拡大の速度の低減を特徴とする、請求項１〜５のいずれかに記載の脳転移の予防または治療剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23268709P | 2009-08-10 | 2009-08-10 | |
| US61/232,687 | 2009-08-10 | ||
| PCT/US2010/044832 WO2011019630A2 (en) | 2009-08-10 | 2010-08-09 | Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501791A JP2013501791A (ja) | 2013-01-17 |
| JP2013501791A5 true JP2013501791A5 (ja) | 2013-09-19 |
Family
ID=42938154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524769A Ceased JP2013501791A (ja) | 2009-08-10 | 2010-08-09 | エンドセリン受容体の阻害剤による星状細胞−腫瘍細胞の処置 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8999934B2 (ja) |
| EP (1) | EP2464218B1 (ja) |
| JP (1) | JP2013501791A (ja) |
| KR (1) | KR20120088665A (ja) |
| CN (1) | CN102510719B (ja) |
| AU (1) | AU2010282744B2 (ja) |
| BR (1) | BR112012003103A2 (ja) |
| CA (1) | CA2770397A1 (ja) |
| CL (1) | CL2012000333A1 (ja) |
| DK (1) | DK2464218T3 (ja) |
| EA (1) | EA023864B1 (ja) |
| ES (1) | ES2543280T3 (ja) |
| HK (1) | HK1171336A1 (ja) |
| HR (1) | HRP20150890T1 (ja) |
| HU (1) | HUE026005T2 (ja) |
| IL (1) | IL217915A0 (ja) |
| IN (1) | IN2012DN01261A (ja) |
| MA (1) | MA33571B1 (ja) |
| MX (1) | MX2012001562A (ja) |
| NZ (1) | NZ598078A (ja) |
| PL (1) | PL2464218T3 (ja) |
| PT (1) | PT2464218E (ja) |
| SG (1) | SG178828A1 (ja) |
| SI (1) | SI2464218T1 (ja) |
| TN (1) | TN2012000054A1 (ja) |
| TW (1) | TWI483938B (ja) |
| WO (1) | WO2011019630A2 (ja) |
| ZA (1) | ZA201200980B (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101563069B1 (ko) * | 2011-02-04 | 2015-10-23 | 액테리온 파마슈티칼 리미티드 | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 |
| CN103796680A (zh) * | 2011-06-21 | 2014-05-14 | 约翰霍普金斯大学 | 用于增强针对赘生物的基于免疫的治疗的聚焦放射 |
| MY190034A (en) | 2015-03-06 | 2022-03-22 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| RU2728796C2 (ru) * | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения опухоли головного мозга |
| PE20180528A1 (es) | 2015-07-13 | 2018-03-19 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina |
| JP6903055B2 (ja) | 2015-08-03 | 2021-07-14 | イーエヌビー・セラピューティクス・インク | Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法 |
| JP6996728B2 (ja) * | 2016-01-07 | 2022-01-17 | 学校法人自治医科大学 | グルコーストランスポーター１発現用アデノ随伴ウイルスベクター |
| MX2018009413A (es) | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Composiciones que contienen tucaresol o sus analogos. |
| WO2017209272A1 (ja) * | 2016-06-03 | 2017-12-07 | 国立大学法人東京大学 | がん転移阻害剤 |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| EP3713571A4 (en) | 2018-01-12 | 2021-08-25 | ENB Therapeutics, Inc. | DEUTERATED COMPOUNDS, COMPOSITIONS AND TREATMENT METHODS FOR CANCERS ASSOCIATED WITH ETBR ACTIVATION |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CN109232546B (zh) | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| CN112062857B (zh) * | 2019-06-10 | 2024-08-09 | 鸿运华宁（杭州）生物医药有限公司 | Eta抗体与bnp的融合蛋白质，及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0116237B8 (pt) * | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| EP2292209A3 (en) * | 2005-09-12 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyramidine-sulfamide |
| TWI441639B (zh) | 2008-02-20 | 2014-06-21 | Actelion Pharmaceuticals Ltd | 用於治療卵巢癌之包含紫杉醇之組合 |
| KR101563069B1 (ko) | 2011-02-04 | 2015-10-23 | 액테리온 파마슈티칼 리미티드 | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 |
-
2010
- 2010-08-09 NZ NZ598078A patent/NZ598078A/xx not_active IP Right Cessation
- 2010-08-09 JP JP2012524769A patent/JP2013501791A/ja not_active Ceased
- 2010-08-09 HU HUE10742690A patent/HUE026005T2/en unknown
- 2010-08-09 TW TW099126507A patent/TWI483938B/zh not_active IP Right Cessation
- 2010-08-09 EP EP10742690.0A patent/EP2464218B1/en not_active Not-in-force
- 2010-08-09 BR BR112012003103A patent/BR112012003103A2/pt not_active IP Right Cessation
- 2010-08-09 CN CN201080040990.1A patent/CN102510719B/zh not_active Expired - Fee Related
- 2010-08-09 SG SG2012009338A patent/SG178828A1/en unknown
- 2010-08-09 US US13/390,072 patent/US8999934B2/en not_active Expired - Fee Related
- 2010-08-09 DK DK10742690.0T patent/DK2464218T3/en active
- 2010-08-09 MX MX2012001562A patent/MX2012001562A/es active IP Right Grant
- 2010-08-09 CA CA2770397A patent/CA2770397A1/en not_active Abandoned
- 2010-08-09 AU AU2010282744A patent/AU2010282744B2/en not_active Ceased
- 2010-08-09 PL PL10742690T patent/PL2464218T3/pl unknown
- 2010-08-09 WO PCT/US2010/044832 patent/WO2011019630A2/en active Application Filing
- 2010-08-09 ES ES10742690.0T patent/ES2543280T3/es active Active
- 2010-08-09 IN IN1261DEN2012 patent/IN2012DN01261A/en unknown
- 2010-08-09 PT PT107426900T patent/PT2464218E/pt unknown
- 2010-08-09 KR KR1020127006203A patent/KR20120088665A/ko not_active Application Discontinuation
- 2010-08-09 SI SI201031003T patent/SI2464218T1/sl unknown
- 2010-08-09 EA EA201270264A patent/EA023864B1/ru not_active IP Right Cessation
-
2012
- 2012-02-02 IL IL217915A patent/IL217915A0/en unknown
- 2012-02-03 TN TNP2012000054A patent/TN2012000054A1/en unknown
- 2012-02-08 CL CL2012000333A patent/CL2012000333A1/es unknown
- 2012-02-09 ZA ZA2012/00980A patent/ZA201200980B/en unknown
- 2012-03-08 MA MA34671A patent/MA33571B1/fr unknown
- 2012-11-29 HK HK12112305.1A patent/HK1171336A1/xx not_active IP Right Cessation
-
2015
- 2015-03-06 US US14/640,662 patent/US20150352113A1/en not_active Abandoned
- 2015-08-20 HR HRP20150890TT patent/HRP20150890T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501791A5 (ja) | ||
| HUE063299T2 (hu) | Daganatok kezelésére vagy megelõzésére szolgáló kombinációs terápia | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
| NZ706836A (en) | Methods of treating cancer | |
| NZ749217A (en) | Androgen receptor modulator and uses thereof | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| MY174018A (en) | Heterocyclic derivates | |
| DK3791896T5 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
| JP2015500225A5 (ja) | ||
| JP2009506054A5 (ja) | ||
| CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| CA2908957C (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| EP3347010A4 (en) | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| JP2014504636A5 (ja) | ||
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| NZ707773A (en) | Methods of treating liver diseases | |
| WO2012158933A3 (en) | Macrocycllc therapeutic agents and methods of treatment | |
| WO2016106357A8 (en) | Combination of raf inhibitors and aurora kinase inhibitors |